6XY.F HBM HLDGS LTD DL-000025

Healthcare Biotechnology Frankfurt Exchange
1.26 EUR
Close of Nov 11, 2026
1.03 1.78
Market cap
EUR 1.10B
P/E
12.6x
P/B
2.87x
ROE
24.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6XY.F undervalued?

Graham number
Price1.26
Graham value0.9936
Premium26.8%

6XY.F trades 26.8% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HBM HLDGS LTD DL-000025 fundamental analysis

No fundamental analysis for HBM HLDGS LTD DL-000025 yet.

HBM HLDGS LTD DL-000025 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HBM HLDGS LTD DL-000025

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively …

Full company profile